Bystander elimination of antigen loss variants in established tumors

Nature Medicine

Volumn 10, Issue 3, 2004, Pages 294-298

  Spiotto, Michael T ^a   Rowley, Donald A ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; 4 HYDROXYTAMOXIFEN; 4-HYDROXYTAMOXIFEN; ANTIESTROGEN; DNA BINDING PROTEIN; DRUG DERIVATIVE; GAMMA INTERFERON; HOMEODOMAIN PROTEIN; MEMBRANE PROTEIN; PERFORIN; PORE FORMING CYTOTOXIC PROTEIN; RAG 1 PROTEIN; RAG-1 PROTEIN; RAG2 PROTEIN, MOUSE; TAMOXIFEN; TUMOR ANTIGEN; V(D)J RECOMBINATION ACTIVATING PROTEIN 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BYSTANDER EFFECT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOSURVEILLANCE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; ANIMAL; C3H MOUSE; C57BL MOUSE; CYTOLOGY; EXPERIMENTAL NEOPLASM; GENETICS; HISTOCOMPATIBILITY; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALIA; MUS MUSCULUS;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; DNA-BINDING PROTEINS; ESTROGEN ANTAGONISTS; HOMEODOMAIN PROTEINS; INTERFERON TYPE II; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PORE FORMING CYTOTOXIC PROTEINS; STROMAL CELLS; T-LYMPHOCYTES, CYTOTOXIC; TAMOXIFEN; TRANSPLANTATION CHIMERA; TUMOR ESCAPE;

EID: 2342485077     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm999     Document Type: Article

References (30)

1. + T-cell-dependent surveillance. Cancer Res. 50, 3851-3858 (1990).
2. Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729 (1996).
3. Nowell, P.C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
4. Khong, H.T. & Restifo, N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3, 999-1005 (2002).
5. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. & Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).
6. Vasmel, W.L., Sijts, E.J., Leupers, C.J., Matthews, E.A. & Melief, C.J. Primary virus-induced lymphomas evade T cell immunity by failure to express viral antigens. J. Exp. Med. 169, 1233-1254 (1989).
7. Lee, K.H. et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol. 161, 4183-4194 (1998).
8. Urban, J.L., Holland, J.M., Kripke, M.L. & Schreiber, H. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation. J. Exp. Med. 156, 1025-1041 (1982).
9. Uyttenhove, C., Maryanski, J. & Boon, T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040-1052 (1983).
10. Schmollinger, J.C. et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl. Acad. Sci. USA 100, 3398-3403 (2003).
11. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and anti-tumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99, 16168-16173 (2002).
12. Jager, E. et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71, 142-147 (1997).
13. Marincola, F.M., Jaffee, E.M., Hicklin, D.J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
14. Ochsenbein, A.F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064 (2001).
15. + T cell adoptive immunotherapy. Immunity 13, 265-276 (2000).
16. Mullen, C.A., Urban, J.L., Van Waes, C., Rowley, D.A. & Schreiber, H. Multiple cancers. Tumor burden permits the outgrowth of other cancers. J. Exp. Med. 162, 1665-1682 (1985).
17. Zhang, Y. et al. Inducible site-directed recombination in mouse embryonic stem cells. Nucleic Acids Res. 24, 543-548 (1996).
18. Spiotto, M.T. et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17, 737-747 (2002).
19. Udaka, K., Wiesmuller, K.H., Kienle, S., Jung, G. & Walden, P. Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J. Immunol. 157, 670-678 (1996).
20. L. Euro. J. Immunol. 33, 17-26 (2003).
21. Garcia, K.C. et al. αβ T cell receptor interactions with syngeneic and allogeneic ligands: affinity measurements and crystallization. Proc. Natl. Acad. Sci. USA 94, 13838-13843 (1997).
22. Dutz, J.P., Tsomides, T.J., Kageyama, S., Rasmussen, M.H. & Eisen, H.N. A cytotoxic T lymphocyte clone can recognize the same naturally occurring self peptide in association with a self and nonself class I MHC protein. Mol. Immunol. 31, 967-975 (1994).
23. Dudley, M.E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
24. Singh, S., Ross, S.R., Acena, M., Rowley, D.A. & Schreiber, H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175, 139-146 (1992).
25. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells. Immunity 12, 677-686 (2000).
26. Plautz, G.E., Mukai, S., Cohen, P.A. & Shu, S. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J. Immunol. 165, 3656-3662 (2000).
27. + T cells mediate graft rejection via a distinct effector pathway. Nat. Immunol. 3, 844-851 (2002).
28. Garin-Chesa, P., Old, L.J. & Rettig, W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA 87, 7235-7239 (1990).
29. Niederman, T.M. et al. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc. Natl. Acad. Sci. USA 99, 7009-7014 (2002).
30. O'Reilly, M.S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994).